{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T08:59:55Z","timestamp":1792313995506,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejim.2023.08.025","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T16:28:58Z","timestamp":1693844938000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-0786","authenticated-orcid":false,"given":"Bel\u00e9n","family":"Atienza-Mateo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-0117","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther F.","family":"Vicente-Rabaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-351X","authenticated-orcid":false,"given":"Rafael B.","family":"Melero-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Ortiz-Sanju\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1004-300X","authenticated-orcid":false,"given":"Ivette","family":"Casafont-Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n C.","family":"Rodr\u00edguez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-5267","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Ferraz-Amaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejim.2023.08.025_bib0001","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/1744666X.2021.1905524","article-title":"Rheumatoid arthritis related interstitial lung disease","volume":"17","author":"Manfredi","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.ejim.2023.08.025_bib0002","doi-asserted-by":"crossref","first-page":"9469","DOI":"10.1038\/s41598-022-13474-w","article-title":"Predictors of long-term prognosis in rheumatoid arthritis-related interstitial lung disease","volume":"12","author":"Chen","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejim.2023.08.025_bib0003","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1038\/s41598-021-88734-2","article-title":"Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis","volume":"11","author":"Cano-Jim\u00e9nez","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejim.2023.08.025_bib0004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/1744666X.2018.1411190","article-title":"Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review","volume":"14","author":"Atzeni","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.ejim.2023.08.025_bib0005","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3390\/jcm9061606","article-title":"The spectrum of interstitial lung disease associated with autoimmune diseases: data of a 3.6-year prospective study from a referral center of interstitial lung disease and lung transplantation","volume":"9","author":"Atienza-Mateo","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.08.025_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00869-2018","article-title":"Predicting outcomes in rheumatoid arthritis related interstitial lung disease","volume":"53","author":"Jacob","year":"2019","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ejim.2023.08.025_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102830","article-title":"Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review","volume":"20","author":"Vicente-Rabaneda","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.ejim.2023.08.025_bib0008","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British society for rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.ejim.2023.08.025_bib0009","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ejim.2023.08.025_bib0010","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orencia accessed on July 6, 2022."},{"issue":"12","key":"10.1016\/j.ejim.2023.08.025_bib0011","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.ejim.2023.08.025_bib0012","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/rheumatology\/keab317","article-title":"Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients","volume":"61","author":"Fern\u00e1ndez-D\u00edaz","year":"2021","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.ejim.2023.08.025_bib0013","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ejim.2023.08.025_bib0014","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ejim.2023.08.025_bib0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American thoracic society\/european respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.08.025_bib0016","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients","volume":"48","author":"Fern\u00e1ndez-D\u00edaz","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ejim.2023.08.025_bib0017","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/jcm9010277","article-title":"Safety of Abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study","volume":"9","author":"Cassone","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2023.08.025_bib0018","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10067-020-05227-9","article-title":"Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis","volume":"40","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.ejim.2023.08.025_bib0019","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3390\/biomedicines10071480","article-title":"Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis\u2013associated interstitial lung disease","volume":"10","author":"Mena-V\u00e1zquez","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.ejim.2023.08.025_bib0020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1164\/rccm.200403-331OC","article-title":"Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia","volume":"171","author":"Jegal","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2023.08.025_bib0021","first-page":"keac208","article-title":"The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease","author":"Brooks","year":"2022","journal-title":"Rheumatology"},{"issue":"22","key":"10.1016\/j.ejim.2023.08.025_bib0022","first-page":"00095","article-title":"Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodology","author":"Narv\u00e1ez","year":"2022","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"1","key":"10.1016\/j.ejim.2023.08.025_bib0023","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12931-021-01879-6","article-title":"Progressive fibrosing interstitial lung disease: prevalence and clinical outcome","volume":"22","author":"Kwon","year":"2021","journal-title":"Respir Res"},{"issue":"17","key":"10.1016\/j.ejim.2023.08.025_bib0024","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.3390\/jcm10173812","article-title":"The extent and diverse trajectories of longitudinal changes in rheumatoid arthritis interstitial lung diseases using quantitative HRCT scores","volume":"10","author":"Lee","year":"2021","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.ejim.2023.08.025_bib0025","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.08.025_bib0026","first-page":"501","article-title":"SER-SEPAR recommendations for the the management of rheumatoid arthritis-related interstitial lung disease","volume":"18","author":"Narv\u00e1ez","year":"2022","journal-title":"Part 2: Treatment Reumatol Clin"},{"issue":"11","key":"10.1016\/j.ejim.2023.08.025_bib0027","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/rheumatology\/kez337","article-title":"Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.ejim.2023.08.025_bib0028","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2023.08.025_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152031","article-title":"Methotrexate use reduces mortality risk in rheumatoid arthritis: a systematic review and meta-analysis of cohort studies","volume":"55","author":"Xu","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ejim.2023.08.025_bib0030","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00296-020-04545-0","article-title":"Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data","volume":"40","author":"Robles-Perez","year":"2020","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.ejim.2023.08.025_bib0031","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.3390\/jcm9103070","article-title":"Rituximab in the treatment of interstitial lung disease associated with autoimmune diseases: experience from a single referral center and literature review","volume":"9","author":"Atienza-Mateo","year":"2020","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.ejim.2023.08.025_bib0032","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J"},{"issue":"11","key":"10.1016\/j.ejim.2023.08.025_bib0033","first-page":"2071","article-title":"Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data","volume":"40","author":"Kalyoncu","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2023.08.025_bib0034","unstructured":"PULMORA trial. Available from: 2023 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04311567."},{"issue":"6","key":"10.1016\/j.ejim.2023.08.025_bib0035","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"22","key":"10.1016\/j.ejim.2023.08.025_bib0036","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"S2213-2600","author":"Solomon","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ejim.2023.08.025_bib0037","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.08.025_bib0038","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1378\/chest.13-1394","article-title":"Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis","volume":"146","author":"Doyle","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2023.08.025_bib0039","article-title":"Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management","volume":"9","author":"Yoo","year":"2022","journal-title":"Eur J Radiol Open"},{"issue":"4","key":"10.1016\/j.ejim.2023.08.025_bib0040","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.chest.2020.04.061","article-title":"Baseline characteristics and progression of a spectrum of interstitial lung abnormalities and disease in rheumatoid arthritis","volume":"158","author":"Kawano-Dourado","year":"2020","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.ejim.2023.08.025_bib0041","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/rheumatology\/keab891","article-title":"Screening for preclinical parenchymal lung disease in rheumatoid arthritis","volume":"61","author":"Esposito","year":"2022","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.ejim.2023.08.025_bib0042","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/rheumatology\/keaa577","article-title":"Rheumatoid arthritis related interstitial lung disease - improving outcomes over 25 years: a large multicentre UK study","volume":"60","author":"Kelly","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejim.2023.08.025_bib0043","first-page":"1970","volume":"18","author":"Jeganathan","year":"2021"},{"issue":"21","key":"10.1016\/j.ejim.2023.08.025_bib0044","first-page":"00194","article-title":"Screening of interstitial lung disease in patients with rheumatoid arthritis: a systematic review","volume":"S2173-5743","author":"Garrote-Corral","year":"2021","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"9","key":"10.1016\/j.ejim.2023.08.025_bib0045","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1007\/s10067-021-05761-0","article-title":"Use of ultrasound to diagnose and monitor interstitial lung disease in rheumatic diseases","volume":"40","author":"Vicente-Rabaneda","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"23","key":"10.1016\/j.ejim.2023.08.025_bib0046","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease","volume":"379","author":"Juge","year":"2018","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523003096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523003096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:41:00Z","timestamp":1760607660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523003096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":46,"alternative-id":["S0953620523003096"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.08.025","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}